HUM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Humana Inc (HUM) is not a strong buy for a beginner investor with a long-term focus at this time. Despite some positive financial growth trends, the stock faces significant headwinds from analyst downgrades, cautious guidance, and lack of clear positive trading signals. The technical indicators are mixed, and options data suggests bearish sentiment. For a long-term investor, it may be prudent to wait for more clarity on the company's financial performance and membership growth impact before committing capital.
The MACD is positive and expanding, suggesting bullish momentum. However, the RSI is neutral at 53.345, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 181.975, with resistance at 190.196 and support at 173.755. Overall, the technical outlook is mixed, with no strong buy signal.
The company reported revenue growth of 11.30% YoY in Q4 2025, and net income improved by 14.86% YoY. EPS also increased by 14.96% YoY. These indicate some positive financial trends.
Analyst sentiment is cautious, with multiple firms lowering price targets significantly. The 2026 EPS guidance of $9 is below consensus expectations, and there are concerns about Medicare Advantage margins and membership growth profitability. Additionally, options data shows bearish sentiment, and technical indicators do not strongly support a buy.
In Q4 2025, Humana's revenue increased by 11.30% YoY to $32.52 billion. Net income improved by 14.86% YoY but remains negative at -$796 million. EPS also improved by 14.96% YoY to -6.61. While there is growth in revenue and improvement in net income, the company remains unprofitable, which is a concern for long-term investors.
Analyst sentiment is predominantly neutral to negative. Multiple firms, including Barclays, Wells Fargo, and Morgan Stanley, have lowered price targets significantly, citing cautious guidance, margin concerns, and uncertainties around membership growth profitability. The consensus view is that the stock may remain range-bound in the near term, with potential clarity emerging in Q2 2026.
